16 Apr 2021 by admin in UncategorizedComments New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours
13 Apr 2021 by admin in UncategorizedComments Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
13 Apr 2021 by admin in UncategorizedComments Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
10 Apr 2021 by admin in UncategorizedComments NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR)
06 Apr 2021 by admin in UncategorizedComments Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
30 Mar 2021 by admin in UncategorizedComments Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters
29 Mar 2021 by admin in UncategorizedComments Tempest and Millendo Announce Proposed Merger Agreement
26 Mar 2021 by admin in UncategorizedComments Design Therapeutics Announces Pricing of Initial Public Offering
22 Mar 2021 by admin in UncategorizedComments Innoforce Pharmaceuticals Completes 625M CNY ($96M) Series A Financing
11 Mar 2021 by admin in UncategorizedComments Adicet Reports Fourth Quarter and Full Year 2020 Financial results
10 Mar 2021 by admin in UncategorizedComments Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B
04 Mar 2021 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2020 Financial Results
04 Mar 2021 by admin in UncategorizedComments NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial
03 Mar 2021 by admin in UncategorizedComments Tempest Therapeutics Announces Clinical Collaboration with Roche to Advance TPST-1120 into a Randomized Combination Study in First-line Hepatocellular Carcinoma
02 Mar 2021 by admin in UncategorizedComments Innoforce and dMed Collaborate to Accelerate the Development of Innovative Therapeutics
16 Feb 2021 by admin in UncategorizedComments Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private
10 Feb 2021 by admin in UncategorizedComments Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent
09 Feb 2021 by admin in UncategorizedComments Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private
02 Feb 2021 by admin in UncategorizedComments Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine
27 Jan 2021 by admin in UncategorizedComments Citrine Medicine Announces Strategic Partnership to bring Alkindi® to China for Use in Pediatric Congenital Adrenal Hyperplasia (CAH)
26 Jan 2021 by admin in UncategorizedComments Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer
14 Jan 2021 by admin in UncategorizedComments Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
11 Jan 2021 by admin in UncategorizedComments Syros Announces Strategic Priorities and Expected Milestones
07 Jan 2021 by admin in UncategorizedComments KIRA PHARMACEUTICALS ANNOUNCES $53.5 MILLION SERIES B+ FINANCING TO ADVANCE LOGIC DRUG DISCOVERY PLATFORM AND PIPELINE OF COMPLEMENT-TARGETED THERAPIES
10 Dec 2020 by admin in UncategorizedComments Crescendo Biologics Expands its Ongoing Collaboration with Takeda
07 Dec 2020 by admin in UncategorizedComments Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma
01 Dec 2020 by admin in UncategorizedComments Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors
